Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Trial of Simeprevir with PegIFN and Ribavirin for HCV Genotype 1
NCT01323244Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2011
- Primary completion
- Mar 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 22
01
Overview
Phase 3, open-label, single-arm trial of simeprevir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained Viral Response 12 weeks after end of treatment. Started Dec 2011; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01323244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01323244.